Northern Bio

Executive Summary

Northern Bio is a preclinical contract research organization (CRO) headquartered in Cambridge, Massachusetts, specializing in in vivo safety assessment and bioanalytical services for novel therapeutics. Since its founding in 2018, the company has built a reputation for advanced surgical techniques, targeted drug delivery, and molecular biology support across multiple therapeutic areas. Operating under both non-GLP and GLP standards, Northern Bio emphasizes customized study design and close client collaboration to accelerate drug and medical device development. Its integrated service model positions it as a reliable partner for biopharma clients seeking high-quality preclinical data to advance their pipelines. While the CRO market is competitive, Northern Bio's focus on specialized, client-centric services differentiates it within the preclinical landscape.

Upcoming Catalysts (preview)

• Q4 2026Expansion of GLP-compliant bioanalytical services to new therapeutic modalities (e.g., gene therapy, cell therapy)70% success
• Q2 2026Strategic partnership with a mid-cap biopharma for multi-year preclinical study agreements60% success
• Q3 2026Launch of a proprietary surgical model platform for CNS drug delivery50% success